Published Issue 1 2020-2021
Topical News
Jennings, Katie. “Pfizer And Moderna Have A Head Start, But The Covid-19 Vaccine Market Is Still Up For Grabs.” Forbes, Forbes Magazine, 16 Nov. 2020, www.forbes.com/sites/katiejennings/2020/11/13/pfizer-has-a-head-start-but-the-covid-19-vaccine-market-is-still-up-for-grabs/?sh=416c30216c13.
With a COVID-19 vaccine on the horizon, there are many things that need to be considered. This article will be reviewing the different phases in vaccine development, Canada’s progress in terms of distributing vaccines and two of the leading vaccines: Pfizer and Moderna.
First, however, how are vaccines made? There are five steps to vaccine development, them being:pre-clinical evaluation, phase 1, phase 2, phase 3, and finally, approval.
Pre-clinical evaluation is the determination of the ability of the prototype product. To put it in simpler terms, it means assessing whether the vaccine’s prototype will be able to function as an effective vaccine. For example, in creating prototypes for cars, the “preclinical” evaluation would be looking at the original car designs and assessing whether they would work as an actual car.
In phase 1, the vaccine is given to a small sample of people. This phase determines the properties of a vaccine, tolerability, and pharmacological parameters. This means that they will test whether a human can tolerate the vaccine, what the vaccine is made of, and whether the vaccine can be distributed to people around the world. Phase 2 includes a larger group of people and is usually used to determine the ability of a vaccine in terms of immunogenicity (the ability to trigger an immune response). Phase 3 is where vaccine makers are finally getting ready to release the vaccine, checking data from phase 2 and preparing for distribution. This is also when the efficacy rate of the vaccine (the percentage of the vaccine success rate) is calculated. Approval is the last step when a vaccine is approved by the governing health body of the country it is being deployed to. In the USA, for example, the Centres for Disease Control and Prevention (CDC) in America has to approve a vaccine before it can be released to the public.
Now that the process of developing a vaccine are understood, how many COVID-19 vaccines are in each stage of development?According to CBC, 164 are in pre-clinical evaluation, 20 are in phase 1, 16 are in phase 2 and 12 are in phase 3–none are approved yet.
This begs the question of where Canada is in terms of developing and securing a COVID-19 vaccine. According to Prime Minister Trudeau, Canada does not have the manufacturing capabilities to make a COVID-19 vaccine. However, Canada has announced that they have reserved millions of vaccines from different companies, including Moderna, BioNTech, Pharma, Pfizer, Novavax and AstraZeneca.
On top of this, the country has also invested in purchasing medical freezers for storing the vaccines. However, Canada is at a disadvantage. Because they do not have the capabilities to make vaccines, Canada will not receive the vaccines they ordered until later. While some countries such as the US and Germany will be rolling out their vaccines as early as December, Canada will not receive it until later. Without specifying a date, Mr. Trudeau announced that Canada would receive a vaccine “as soon as possible”.
Bronskill, Jim. “Trudeau Announces $1.1B to Fund COVID-19 Vaccine Development, Tracking of Cases.” Global News, Global News, 23 Apr. 2020, globalnews.ca/news/6857058/coronavirus-canada-science-vaccine-funding/.
Jennings, Katie. “Pfizer And Moderna Have A Head Start, But The Covid-19 Vaccine Market Is Still Up For Grabs.” Forbes, Forbes Magazine, 16 Nov. 2020, www.forbes.com/sites/katiejennings/2020/11/13/pfizer-has-a-head-start-but-the-covid-19-vaccine-market-is-still-up-for-grabs/?sh=416c30216c13.
So now, let's talk about the two largest candidates for a COVID-19 vaccine, Pfizer and Moderna. Pfizer is an RNA vaccine.
An RNA vaccine uses something called antigens - the things that cause an infection to instigate an immune response against the virus.
Exposing the body to antigens leads to the production of antibodies specifically directed against them, These antibodies can immediately recognize the virus and destroy it quickly. This vaccine has a 95% efficacy rate. This means that if 100 people were vaccinated with Pfizer, 95 of them would be immune to COVID-19. The vaccine's efficacy rate was consistent across all ages, genders and ethnicities. However, this vaccine has to be stored in -70º celsius medical freezers. This makes it harder to transport, and therefore distribute. According to Dr. Lynora Saxinger, an infectious disease specialist, the Pfizer vaccine is a very promising vaccine candidate.
The Moderna vaccine works similarly to the Pfizer vaccine. It uses RNA technology with a 94.5% efficacy rate. This vaccine can be stored at -20 celsius in regular freezers, making it more practical to distribute and administer then the Pfizer vaccine.
Both of these vaccine candidates require two doses, each shot 28 days apart. Half of the vaccine is used in the first shot while the other half is used in the second shot. This is so that the body is not overloaded with too many dead viruses.
These vaccines might not be a silver bullet, but they are certainly a welcomed light at the end of the dark COVID-19 tunnel.
Thomas, Katelyn, et al. “Unfounded Hostage Threat Causes Major Police Operation in Montreal, Hospital 'Code Orange' Warning.” Montreal, CTV News, 14 Nov. 2020, montreal.ctvnews.ca/unfounded-hostage-threat-causes-major-police-operation-in-montreal-hospital-code-orange-warning-1.5188063.